We are live on ! Find out more
BBH icon

VanEck Biotech ETF

98 hedge funds and large institutions have $115M invested in VanEck Biotech ETF in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.61% less ownership

Funds ownership: 35.45%34.84% (-0.61%)

6% less funds holding

Funds holding: 10498 (-6)

11% less capital invested

Capital invested by funds: $130M → $115M (-$14.3M)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

40% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 25

57% less call options, than puts

Call options by funds: $276K | Put options by funds: $644K

Holders
98
Holders Change
-6
Holders Change %
-5.77%
% of All Funds
1.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
15
Reduced
25
Closed
16
Calls
$276K
Puts
$644K
Net Calls
-$368K
Net Calls Change
-$2.77M

BBH Hedge Fund Activity: Q2 2025 in Review

98 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2025, worth a combined $115M — down 11% from $130M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of BBH and 10 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 15 added.

The largest buyer was Raymond James Financial, adding an estimated $7.19M. The largest seller was Morgan Stanley, cutting an estimated $6.8M.

  • 98 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2025, down from 104 in Q1 2025.
  • Funds reported $115M of VanEck Biotech ETF stock for Q2 2025, down 11% quarter-over-quarter.
  • 10 funds opened new VanEck Biotech ETF positions in Q2 2025 and 16 closed out, a net change of -6 holders.
  • The largest VanEck Biotech ETF buyer in Q2 2025 was Raymond James Financial, an estimated $7.19M added.
  • The largest VanEck Biotech ETF seller in Q2 2025 was Morgan Stanley, an estimated $6.8M sold.

Based on aggregated 13F filings for Q2 2025.